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Schinus terebinthifolia leaf lectin 
(SteLL) has anti-infective action 
and modulates the response of 
Staphylococcus aureus-infected 
macrophages
isana Maria de Souza feitosa Lima1, Adrielle Zagmignan1, Deivid Martins Santos1, 
Hermerson Sousa Maia1, Lucas dos Santos Silva1, Brenda da Silva cutrim1, 
Silvamara Leite Vieira1, clovis Macêdo Bezerra filho2, eduardo Martins de Sousa1, 
thiago Henrique napoleão2, Karen Angeliki Krogfelt  3,4, Anders Løbner-olesen5, 
patrícia Maria Guedes paiva2 & Luís cláudio nascimento da Silva  1*
Staphylococcus aureus is recognized as an important pathogen causing a wide spectrum of diseases. 
Here we examined the antimicrobial effects of the lectin isolated from leaves of Schinus terebinthifolia 
Raddi (SteLL) against S. aureus using in vitro assays and an infection model based on Galleria mellonella 
larvae. the actions of SteLL on mice macrophages and S. aureus-infected macrophages were also 
evaluated. SteLL at 16 µg/mL (8 × Mic) increased cell mass and DnA content of S. aureus in relation 
to untreated bacteria, suggesting that SteLL impairs cell division. Unlike ciprofloxacin, SteLL did not 
induce the expression of recA, crucial for DnA repair through SoS response. the antimicrobial action of 
SteLL was partially inhibited by 50 mM N-acetylglucosamine. SteLL reduced staphyloxathin production 
and increased ciprofloxacin activity towards S. aureus. this lectin also improved the survival of G. 
mellonella larvae infected with S. aureus. Furthermore, SteLL induced the release of cytokines (IL-6, 
IL-10, IL-17A, and TNF-α), nitric oxide and superoxide anion by macrophagens. the lectin improved the 
bactericidal action of macrophages towards S. aureus; while the expression of IL-17A and IFN-γ was 
downregulated in infected macrophages. these evidences suggest SteLL as important lead molecule in 
the development of anti-infective agents against S. aureus.
Staphylococcus aureus is recognized as an important pathogen causing a wide spectrum of diseases including 
cutaneous and blood stream infections1,2. This versatility is ensured by the high ability of this microorganism to 
acquire drug resistance and to produce virulence factors that are regulated by complex genetic networks2–5. The 
multiple virulence factors identified in S. aureus play different roles during the infection such as adhesion, host 
lesions and evasion of the immune system, even from professional phagocytes such as macrophages6–8.
It has been reported that the dissemination of S. aureus is associated to the capacity of this bacterium to sur-
vive and replicate inside the phagocytes (in both phagosome and/or cytoplasm), and modulate important cellular 
mechanisms such as autophagy, apoptosis and pyronecrosis9–11. S. aureus is also able to release several effector 
molecules to suppress or enhance cytokine production (including IL-1β, IL-17 and TNF) as well as to dam-
age immune cells and host tissues6,12–14. Thus, compounds able to improve and/or regulate the cellular immune 
response have been pointed out as promising lead drugs for treatment of microbial infections and also to improve 
the general understanding related to host-pathogen interactions15–19.
1Programas de Pós-Graduação, Universidade Ceuma, São Luís, Maranhão, Brazil. 2Departamento de Bioquímica, 
Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. 3Department of Viral and Microbial Diagnostics, 
Statens Serum Institut, Copenhagen, Denmark. 4Department of Science and Environment, Roskilde University, 
4000, Roskilde, Denmark. 5Department of Biology, Section for Functional Genomics, University of Copenhagen, 
Copenhagen, Denmark. *email: luiscn.silva@ceuma.br
open
2Scientific RepoRtS |         (2019) 9:18159  | https://doi.org/10.1038/s41598-019-54616-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Plants are important sources of molecules to be used for drug development due their high chemical variability 
and diverse action mechanisms20,21. Among plant derived compounds, lectins have displayed a wide range of 
biotechnological applications, including antimicrobial and immunomodulatory actions16,19,22–27. Previously, the 
isolation of SteLL, an N-acetylglucosamine-binding (NAG) lectin, from leaves of Schinus terebinthifolia Raddi 
(Anacardiaceae) was reported.
SteLL is a 14 kDa glycoprotein and the antimicrobial activity of this protein was reported towards both 
Gram-positive and Gram-negative bacteria and Candida albicans25. SteLL also affected the survival and nutri-
tion of the beetle Sitophilus zeamais adults28. Recently, the antitumoral activity of SteLL was shown in sarcoma 
180-bearing mice. The authors reported that the treatment with SteLL did not induce hematological changes nor 
genotoxic effects in mice, advocating for the safety of in vivo use of this lectin29.
This present work provides insights into the in vitro effects of SteLL on S. aureus and evaluates the phenotypic 
response induced by this lectin in macrophages uninfected and/or infected by S. aureus. In addition, the in vivo 
activity of this lectin against S. aureus is reported using Galleria mellonella larvae (Lepidoptera: Pyralidae) as 
infection model.
Results
SteLL induced changes in the cell size/DnA content ratio of S. aureus. As previously reported25, 
SteLL was able to inhibit the growth of all S. aureus strains tested (S. aureus 8325-4, S. aureus ATCC 6538, S. 
aureus ATCC 29312) with a MIC (minimum inhibitory concentration) of 2 µg/mL. A flow cytometry-based assay 
was performed to assess the effects of SteLL on cell size (seen by mean light scattering detected in LS1) and DNA 
content (seen by the fluorescence intensity in FL2 channel) of S. aureus. Ciprofloxacin (inhibitor of DNA replica-
tion) and chloramphenicol (inhibitor of protein synthesis) were used as controls in this assay (Table 1 and Fig. 1).
The exposure of S. aureus to ciprofloxacin at MIC resulted in significantly increase in cell mass, while the DNA 
content decreased when compared with untreated cells. This resulted in a decrease in the cellular DNA concen-
tration (DNA/mass ratio = 0.41) compared to untreated bacteria (DNA/mass ratio = 0.71). Bacteria treated with 
chloramphenicol did not alter cell size as cell division requires protein synthesis and hence was blocked. In these 
bacteria, the cellular DNA content increased (DNA/mass ratio = 1.20), which is consistent with a DNA replica-
tion arrest specifically at the level of initiation. Consequently, runout chromosome synthesis was observed and 
the bacterial cells end up with integral numbers of fully replicated chromosomes (Fig. 1C).
Cells treated with SteLL did not follow any of these profiles (Fig. 1D,E). A significant increase (31%) on cell 
size was observed in bacteria treated with SteLL at 8 × MIC (16 µg/mL), this was accompanied by a similar 
increase in DNA content (39%), and consequently the DNA concentration remained almost unchanged in these 
cells (DNA/mass ratio = 0.75) (Table 1). The effects of SteLL on S. aureus cell size were also confirmed by fluo-
rescence microscopy (Fig. 2), where cells treated with the lectin (Fig. 2C,D) appeared with increased size when 
compared with control cells (Fig. 2A).
We also evaluated whether sub-inhibitory concentration of SteLL (0.5 × MIC) had any effect on the SOS 
response, a pathway associated with acquisition of drug resistance and virulence phenotypes. After 3 h of treat-
ment, recA transcription determined from a recA-lacZ transcriptional fusion was not altered by SteLL (Fig. 3). On 
the other hand, ciprofloxacin (a DNA damaging agent) induced more than 5-fold increase in recA transcription. 
These results revealed that SteLL, unlike ciprofloxacin, did not affect DNA integrity and thus did not induce any 
SOS-related mutagenic pathways.
SteLL increased ciprofloxacin activity against S. aureus. Checkerboard assays were performed to 
evaluate the interaction of SteLL with two selected antibiotics: ciprofloxacin and ampicillin. The MIC values for 
these two drugs towards S. aureus 8325-4 were 0.78 µg/mL and 25 µg/mL, respectively. A synergistic activity was 
observed when combining SteLL with ciprofloxacin (ΣFIC: 0.47); while an additive effect was found between 
SteLL and ampicillin (ΣFIC: 0.53).
We subsequently performed time-kill assays on S. aureus strain 8325-4 using SteLL (2 × MIC and 8 × MIC), 
ciprofloxacin (2 × MIC), and combinations of these two agents (2 × MIC SteLL + 2 × MIC ciprofloxacin and 
8 × MIC SteLL + 2 × MIC ciprofloxacin). Both SteLL concentrations delayed the onset of growth. After 7.5 h, 
the reductions of bacterial counts by both SteLL concentrations were approximately 2 log CFU/mL (relative to 
untreated cells). In contrast, ciprofloxacin (2 × MIC) strongly reduced the bacterial growth in a time-dependent 
manner (Fig. 4A,B).
When SteLL was combined at 2 × MIC, it did not induce any effect on ciprofloxacin (2 × MIC) bacteri-
cidal action (ΔLC were less than 1 log CFU/mL when compared with ciprofloxacin-treated cells). On the other 
Untreated 
cells
CAM
(1 × MIC)
CIP
(1 × MIC)
SteLL
(2 × MIC)
SteLL
(8 × MIC)
Cell mass 426.1 ± 36.1a 470.0 ± 26.6a 638.0 ± 44.7b 492.3 ± 62.2a 560.6 ± 65.2b
DNA content 303.8 ± 41.5a 562.2 ± 31.0b 264.4 ± 36.4a 383.1 ± 73.1a 422.5 ± 74.4b
DNA/mass ratio 0.71 1.20 0.41 0.78 0.75
Table 1. Effects of SteLL on cell size and DNA content of S. aureus 8325-4 during exponential growth. Cell mass 
and DNA content was measured by flow cytometry using forward scattering (at LS1 detector) and fluorescence 
intensity (at FL2 channel) and are expressed by arbitrary units (a.u.). Legend: CAM: Chloramphenicol; CIP: 
Ciprofloxacin; SteLL: Schinus terebinthifolia leaf lectin. In each row the values with significant differences 
(p < 0.05) are indicated by different letters.
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hand, the combination of ciprofloxacin at 2 × MIC and SteLL at 8 × MIC was more effective than ciprofloxacin 
alone. For this combination, significant reductions were observed at all evaluated times, with the maximal effect 
observed after 4.5 h of incubation. At this time a ΔLC of 1.38 log CFU/mL relative to cells treated with ciprofloxa-
cin alone. Thus, at this concentration SteLL exhibited an additive bactericidal effect resulting in a faster reduction 
in viable bacteria during the first hours of incubation (Fig. 4B).
In order to evaluate the involvement of carbohydrate-binding domain, we compared the effects of SteLL 
(8 × MIC) on S. aureus growth in the presence of 50 mM NAG. The antimicrobial action of SteLL was partially 
inhibited by NAG with inhibition index (IN%) of 20.67 ± 1.07, 24.19 ± 1.97 and 36.91 ± 3.35 after incubation of 
4 h, 6 h and 8 h (Fig. 4C).
SteLL inhibits staphyloxanthin production. Next, we evaluated whether sub-inhibitory SteLL concen-
trations (0.065 × MIC, 0.125 × MIC, 0.25 × MIC and 0.5 × MIC) could inhibit the production of staphyloxanthin, 
the golden pigment of S. aureus ATCC 29312. SteLL induced a dose-dependent reduction in staphyloxanthin 
production relative to untreated bacteria (Fig. 5A). The reductions ranged from 48.78% to 82.88% (Fig. 5B). The 
treatment with the highest tested concentration of SteLL (0.5 × MIC) reduced the staphyloxanthin content to 
around 18% (in comparation to untreated bacteria), resulting in almost colorless S. aureus cells.
SteLL increased the release of nitric oxide and superoxide by mice macrophages. The mac-
rophage viability was not affected by any tested SteLL concentrations (2–16 µg/mL) (data not shown). On the 
other hand, the treatment of macrophages with different concentrations of this lectin resulted in a significant 
increase in NO production in relation to untreated cells (Fig. 6A). Maximum NO production was observed in the 
presence of SteLL at 8 µg/mL and 16 µg/mL. At these concentrations, the levels of NO were similar (p > 0.05) to 
those produced by M1 macrophages.
The induction of mitochondrial superoxide by SteLL was evaluated using the MitoSOX fluorescent probe. 
The macrophages were incubated for 30 min with SteLL at 8 µg/mL and 16 µg/mL. As shown in Fig. 6B, only the 
treatment with SteLL at 16 µg/mL significantly enhanced superoxide production by the macrophages (increase 
of 40%).
Figure 1. Effects of SteLL and selected antimicrobials on DNA content of S. aureus 8325-4. (A) Exponentially 
growing cells; (B) Cells treated with 0.78 µg/mL ciprofloxacin for 3 h; (C) Cells treated with 12.5 µg/mL 
chloramphenicol for 3 h; (D) Cells treated with 2 × MIC SteLL (4 µg/mL) for 3 h; (E) Cells treated with 8 × MIC 
(16 µg/mL) SteLL for 3 h.
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SteLL increased the bactericide activity of mice macrophages. Next, we evaluated the effects 
of SteLL on S. aureus-infected macrophages. SteLL at 16 µg/mL significantly increased the NO levels released 
by S. aureus-infected macrophages (p > 0.05) (Fig. 6C). The highest tested concentration of SteLL (16 µg/mL) 
also induced a significant decrease in bacterial load in the supernatant (7.49 ± 0.33 log CFU/mL) in relation 
to untreated S. aureus-infected macrophages (13.35 ± 0.24 log CFU/mL) (Fig. 6D). However, the intracellular 
amount of S. aureus was not altered by SteLL treatment (Fig. 6D). The same response was observed in mac-
rophages infected with S. aureus ATCC 6538 and treated with SteLL (Supplementary Fig. 1). These results 
Figure 2. Effects of SteLL on cell size of S. aureus 8325-4. (A) Exponentially growing cells; (B) Cells treated 
with 0.78 µg/mL ciprofloxacin for 3 h; (C) Cells treated with 2 × MIC SteLL (4 µg/mL) for 3 h; (D) Cells treated 
with 8 × MIC (16 µg/mL) SteLL for 3 h.
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Figure 3. Effects of SteLL on recA expression of S. aureus. The expression of recA were performed using a 
derivative S. aureus 8325-4 strain carrying a recA::lacZ fusion. β-galactosidase activity was measured using 
ONPG. (*) Indicates significant differences in relation to control cells (p < 0.05).
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indicated that the reduction of bacteria in supernatant of SteLL-treated macrophages is related with the increased 
release of reactive species.
SteLL modulated cytokine release by uninfected macrophages or Staphylococcus 
aureus-uninfected macrophages. We selected the most active concentration of SteLL (16 µg/mL) to eval-
uate its influence on cytokine release pattern of macrophages uninfected and infected with S. aureus. For unin-
fected macrophages, the treatment with this dose resulted in a significant enhancement of IL-6, IL-10, IL-17A, 
and TNF-α compared to untreated cells (p > 0.05) (Fig. 7A,B,C,E). The levels of IFN-γ were also higher in the 
supernant of SteLL-treated cells, although no statitical differences were found when compared with the values 
obtained for control cells (Fig. 7D). The lectin did not influence the levels of IL-4 and IL-12 (data not shown).
The macrophages infected with S. aureus expressed high levels of IL-6, IL-10, IL-17A, and TNF-α (Fig. 7). 
The roles of theses cytokines in pathogenesis of S. aureus have been described previously30–32. The level of IFN-γ 
was also increased by S. aureus infection (about 2-fold). SteLL was able to downregulate the expression of IL-17A 
(Fig. 7B) and IFN-γ (Fig. 7D) by infected macrophages, while the levels of the other tested cytokines were also 
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Figure 4. Antimicrobial action of SteLL against S. aureus. (A) Time-kill curves for 2 × MIC SteLL (4 µg/mL) 
alone or in combination with 2 × MIC ciprofloxacin. (B) Time-kill curves for 8 × MIC SteLL (16 µg/mL) alone 
or in combination with 2 × MIC ciprofloxacin. (C) Effects of N-acetylglucosamine (NAG) on antimicrobial 
action of 8 × MIC SteLL (16 µg/mL).
Figure 5. Effects of SteLL on staphyloxanthin production by S. aureus ATCC 29312. (A) Qualitative assay; (B) 
Quantitative assay. (*) Indicates significant differences in relation to control cells (p < 0.05).
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reduced albeit not in a significant manner. It is important to highlight that SteLL did not totally inhibit the release 
of IL-17A and IFN-γ; in fact, their levels were reduced to approximately what was found in the supernatant of 
control cells.
SteLL protected Galleria mellonella larvae against Staphylococcus aureus infection. To finally 
show the treatment efficacy of SteLL, we employed an infection assay using G. mellonella larvae. This model has 
been widely used to study microbial pathogenesis33 and to assess the in vivo activity of antimicrobial agents34,35. 
Uninfected larvae inoculated with PBS or SteLL exhibited similar survival curves (p > 0.05). On the other hand, 
infection with S. aureus 8325-4 reduced the larval viability by 30%, 80% and 100%, on day 1, 2 and 3, respectively. 
The median survival of this group was 2 days.
The single-dose treatment using 0.2 mg/kg SteLL (corresponding to the administration of 10 µL of a SteLL 
solution at 2 × MIC) increased the survival of S. aureus-infected insects. For this group, the median survival was 
not possible to be defined, and only a 30% reduction in survival was recorded after 3 days (Fig. 8A). The survival 
curves of SteLL-treated larvae and S. aureus-infected group were significantly different (p < 0.05).
Next, we evaluated the number of S. aureus colonies in the hemolymph of larvae. The untreated larvae 
infected with S. aureus exhibited increased levels of bacteria in hemolymph during the experiment (Fig. 8B). The 
Figure 6. Effects of SteLL on different responses of mice peritoneal macrophages. (A) Nitric oxide release by 
mice macrophages induced by SteLL. (B) Production of mitochondrial superoxide anion by mice peritoneal 
macrophages induced by SteLL. (C) Nitric oxide release by S. aureus-infected macrophages induced by SteLL. 
(D) Effects of SteLL on bactericidal activity of mice peritoneal macrophages towards extracellular and (ExSa) 
intracellular (IntraSa) S. aureus. M1 macrophages: macrophages treated with LPS + INF-γ. M2 macrophages: 
macrophages treated with IL-4 + IL-13. Con: untreated cells; Sa: S. aureus. (*) Indicates significant differences 
in relation to M2 macrophages (p < 0.05). (**) Indicates significant differences in relation to untreated 
macrophages (p < 0.05). (#) Indicates significant differences in relation to S. aureus-infected cells without SteLL 
treatment (p < 0.05).
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treatment with SteLL was able to significantly inhibit the bacteria growth (p < 0.05). During the first two days the 
bacterial load in SteLL-treated animals remained the same as at time of inoculation and only a small increase was 
observed in the third day (about 1 log CFU/mL). This effect is in accordance to the effect of SteLL in the time kill 
assay (Fig. 3). In this sense, SteLL treatment reduced the S. aureus proliferation in larvae hemolymph resulting in 
increased animal survival.
Figure 7. Effects of SteLL on cytokine release of mice peritoneal macrophages infected or not with S. aureus. 
(A) IL-10; (B) IL-17A; (C) TNF; (D) INF-γ; (E) IL-6. Con: untreated cells; Sa: S. aureus. (*) Indicates significant 
differences in relation to control cells (p < 0.05). (#) Indicates significant differences in relation to S. aureus 
infected cells (p < 0.05).
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Discussion
In this study, we evaluated the in vitro effects of SteLL on S. aureus and the responses induced by this protein in 
two models of infections (using macrophages and G. mellonella). SteLL is purified from leaves of S. terebinthifolia, 
a medicinal plant widely used in Northeastern Brazilian (where it is popularly known as “Aroeira da praia”) to 
treat skin wounds and inflammation36. Besides SteLL, other products derived from S. terebinthifolia have exhib-
ited antimicrobial activity such as essential oils and some purified compounds37–39.
We employed a flow cytometry-based method to analyze whether SteLL could induce any effect on cell size 
and DNA content40. Proper cell cycle control is essential to ensure the generation of two identical daughter cells 
as result of cell division41–43. Perturbations in cell cycle regulation are therefore deleterious for bacterial prolifer-
ation; and thus the proteins involved in this pathway constitute potential targets for drug action44. We observed 
that SteLL induced significant increases in both the cell size and DNA content after 3 hours of incubation. These 
effects were confirmed by fluorescence microscopy and may indicate impairment of cell division (since both DNA 
and cell mass are increased), a kind of response that has been described for other antimicrobial agents such as 
targocil, a cell wall stressor45.
The ability to bind N-acetylglucosamine residues has been associated with the bacteriostatic properties of 
chitin-binding lectins (such as SteLL)25,26,46, since high amount of peptidoglycan in S. aureus cell wall provides 
multiples targets for interactions. We demonstrated that 50 mM NAG partially inhibited the antimicrobial action 
of SteLL. Thus, it is possible to hypothesize that SteLL binds N-acetylglucosamine residues present in cell wall and 
disturbs the process of cell division.
In addition, SteLL treatment did not induce the expression of recA which is instrumental in triggering the 
SOS response. RecA detects ssDNA generated by DNA degradation or inhibition of DNA replication, stimulates 
LexA autocleavage which in turn leads to derepression of a number of LexA regulated genes. These genes encode 
enzymes involved in DNA repair and mutagenesis (reviewed by Simmons et al.47). Taken together, these findings 
indicated that SteLL may inhibit bacterial growth by impairing division without affecting DNA structure.
Since SteLL inhibits the growth of S. aureus, we evaluated whether this lectin could affect the activity of antibi-
otics in clinical use. The combinatory effects of SteLL and the antibiotics ciprofloxacin or ampicillin were assessed 
using checkboard and time-kill experiments. Initially, we found that this lectin improved the action of ampicillin 
(β-lactam) and ciprofloxacin (quinolone) through additive and synergistic effects, respectively. SteLL at 16 µg/mL 
(8 × MIC) could also increase the bactericidal properties of ciprofloxacin, however, this action was only observed 
during the first hours. The synergistic interactions with antibiotics have been reported only for few plant lectins, 
including the lectins extracted from Alpinia purpurata (ApuL)24 and Vatairea macrocarpa (VML)48.
Another effect of SteLL on S. aureus physiology is the inhibition of staphyloxanthin production, a carotenoid 
pigment encoded by the crtOPQMN operon. Staphyloxanthin has been associated with the protection against 
oxidant attack promoted by immune cells49, which brought a new light in the use of this pigment as target for drug 
development34,50. Some plant derived compounds have inhibitory effects on staphyloxanthin34,51,52, however, this 
is the first report of a similar action for a plant lectin.
Given the well known ability of plant lectins to alter the phenotic responses of immune cells, we examined the 
effects of SteLL on macrophages and S. aureus-infected macrophages. The results showed that SteLL induced the 
the release of cytokines (IL-6, IL-10, IL-17A, and TNF-α) and reactive species (nitric oxide, superoxide anion) by 
uninfected macrophagens. The ability of plant lectins to alter the macrophage responses have been demonstrated 
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Figure 8. Effects of SteLL on survival (A) and bacteria load in hemolymph (B) of G. mellonella larvae infected 
with S. aureus. In all experiments the larvae were infected with a S. aureus 8325-4 suspension (10 μL of 1.0 × 105 
CFU/mL) and treated with SteLL at 0.2 mg/kg. (*) Indicates significant differences in relation to control cells 
(p < 0.05).
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by other authors18,19,53. The effects of SteLL on nitric oxide and superoxide anion production may be related to the 
improvement of macrophages bactericidal action, since these reactive species play essential roles in the defense 
against infectious diseases54,55.
Importantly, SteLL modulated the expression of two proinflammatory cytokines (IL-17A and IFN-γ) in 
infected macrophages. In the context of S. aureus infectious, IL-17A is essential for antimicrobial peptides produc-
tion and bacterial clearance56, while IFN-γ increase the macrophages response against S. aureus57. Intriguingly, 
the overproduction of both cytokines can also exacerbate the severity of some infections14,58. For example, S. 
aureus phenol-soluble modulins that induce high levels of IL-17 leading to skin inflammatory response13.
The excess of IFN-γ is also related to the harmful inflammation state associated with the damage of essential 
organs (such as liver and kidney)59. Recent evidences suggested that IFN-γ favored the outgrowth of S. aureus58. 
Thus, inhibition of the expression of both IFN-γ and IL-17A has been reported as a beneficial effect in several 
models of S. aureus-induced infection59,60.
Although the molecular mechanism underlying the suppression of IL-17A and IFN-γ induced by lectin treat-
ment in macrophages infected with S. aureus remains to be elucidated, it is possible that decreased levels of these 
cytokines help to attenuate the deleterious effects of persistent inflammatory responses at the site of infection. 
Furthermore, because the non-infected cells treated with SteLL presented different cytokine profiles than those 
found in the S. aureus-infected cells treated with SteLL, it is likely that bacterial components also contribute to 
modulation of the macrophage response.
These paradoxical effects on the production of inflammatory mediators when comparing uninfected and 
infected hosts have been observed for other plant lectins16,18,19. For instance, the lectin isolated from Cratylia 
mollis (Cramoll) has been described as pro-inflammatory agent in in vitro and in vivo models18,61–63; however the 
treatment with this protein was shown to reduce the release of cytokines (such as TNF-α, IL-6) in experimental 
models of infection induced by S. aureus (using peritoneal cells)18 and Cryptococcus gatti (using mice)64.
Similarly, the lectin from Canavalia brasiliensis (ConBr) induced different responses in Salmonella 
enteritidis-infected and uninfected macrophages. The exposition of uninfected macrophages to ConBr resulted 
in high levels of mRNA transcripts for IL-6 (in relation to untreated and uninfected macrophages). However, S. 
enteritidis-infected macrophages treated with this lectin exhibited lower levels of IL-6 gene transcription when 
compared to untreated S. enteritidis-infected cells. ConBr treatment also suppressed the transcription of IL-10 
gene in macrophages infected with S. enteritidis19.
Material and Methods
S. aureus strains. S. aureus 8325-4, S. aureus ATCC 6538 and S. aureus ATCC 29312 were used for antimi-
crobial evaluation. The S. aureus 8325-4 derivative strain carrying a recA::lacZ transcriptional fusion in its chro-
mosome65 was kindly shared by Prof. Dr. Hanne Ingmer. The S. aureus ATCC 29312 was used for staphyloxanthin 
quantification, since S. aureus 8325-4 is a weak producer due a natural deletion in rsbU66.
Lectin purification. SteLL was purified from dried leaves of S. terebinthifolia (collected in Recife, Brazil) 
using the methodology reported by Gomes et al.25. The leaves were obtained from specimens grown in the cam-
pus of the ‘Universidade Federal de Pernambuco’ at Recife, Brazil (8°02′55.9″S 34°56′48.4″W). The plant collec-
tion was authorized by ‘Instituto Chico Mendes de Conservação da Biodiversidade’ from Brazilian Ministry of 
Environment (license number: 36301).
For SteLL purification, the powder from dried leaves (20 g) was suspended in a saline solution (0.15 M NaCl) 
and submitted to agitation at 4 °C. After 16 h, the filtered extract was centrifuged (3000 × g for 15 min) and then 
submitted to chitin column (Sigma-Aldrich, MO, USA). The elution was performed using acetic acid (1 M) and 
SteLL was obtained after dialysis (10 kDa cut-off membrane; Sigma-Aldrich) against distilled water (4 h, 4 °C) and 
in sequence against 0.15 M NaCl (4 h, 4 °C). The protein concentration was determined according to Lowry et al. 
using a standard curve of bovine serum albumin (31.25‒500 μg/mL)67.
Antibacterial activity and combinatory effects with antibiotics. MIC determination. The anti-
microbial activity of SteLL was confirmed by determination of the Minimum Inhibitory Concentration (MIC) 
against S. aureus strains (S. aureus 8325-4, S. aureus ATCC 6538 and S. aureus ATCC 25923) using broth microdi-
lution assay25. Briefly, serial dilutions of SteLL were prepared in 96-wells plates containing Luria-Bertani (LB) 
broth to obtain concentrations ranging from 128 to 0.25 µg/mL. Following, each well received 10 μL of a microbial 
suspension (resulting in a bacterial load of approximately 1.0 × 107 CFU/mL for each well). Bacterial growth was 
detected measuring the optical density at 600 nm (OD600).
The antimicrobial action of SteLL was also evaluated in the presence of NAG, to evaluate the participation of 
carbohydrate-binding domain. For this, SteLL (16 µg/mL) was pre-incubated with 50 mM NAG. After 1 h, the 
bacteria were added as described for MIC determination. The bacterial growth was determined after 3 h, 6 h and 
9 h of incubation. The inhibition index (IN%) was calculated using the following equation:
− × ×+Inhibition index(IN%): 100 [(BAC 100/BAC)/(BAC 100/BAC )]SteLL SteLL NAG NAG
Where, BAC is the growth of untreated bacteria; BACSteLL is the growth of bacteria in the presence of SteLL; 
BACNAG is the growth of untreated bacteria in presence of NAG; BACSteLL+NAG BACSteLL is the growth of bacteria 
in the presence of SteLL and NAG.
Combinatory effects. The interaction between SteLL and drugs (ciprofloxacin or ampicillin) were evaluated 
using checkerboard assay. Fractional inhibitory concentration index (FICI) was assessed algebraically by the sum 
of the single FIC values for each sample present in the well:
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where “L” is the concentration (µg/mL) of SteLL in a given well, and MICL represents the control MIC of SteLL 
alone. “D” is the concentration of the tested drug in a given well, and MICD represents the control MIC of the 
tested drug alone. FICI mean (ΣFIC) is derived by averaging the FICI values along the growth–no growth inter-
face. Data interpretation: ΣFIC ≤ 0.5: synergism (syn); 0.5 < ΣFIC ≤ 1: addition (add); 1 < ΣFIC < 4: noninter-
action (non); ΣFIC ≥ 4: antagonism (ant)68.
Time-kill studies. Overnight cultures of S. aureus 8325-4 were diluted 1:100 in LB broth and placed in a shaking 
water bath at 37 °C. When the cultures reached an OD600 of 0.1 they were distributed in fresh LB broth containing 
increasing concentrations of SteLL (2 × and 8 × MIC) or ciprofloxacin (2 × MIC) alone or combined. The cell 
growth was monitored by plating 4 µL of 10-fold-diluted suspensions from each tube in quadruplicate and follow-
ing the OD600 at 0, 1.5 h, 3.0 h, 4.5 h, 6.0 h and 7.5 h. The plates were incubated at 37 °C for 24 h. After this period, 
the colonies were counted for the calculation of CFU/mL. The bactericidal combinatory effects was assessed by 
variation on Log CFU/mL (ΔLC) and the effects were recorded as synergistic if ΔLC ≥ 2 log CFU/mL; additive 
if ΔLC was between 1 and 2 log CFU/mL); indifference if ΔLC = ±1 log CFU/mL; or antagonism if ΔLC > −1 
log CFU/mL69.
Effects of SteLL on cell size and DNA content. The possible effects of SteLL on cell size and DNA 
content of S. aureus were evaluated using flow cytometry and fluorescence microcopy. For flow cytometry, expo-
nentially growing cells of S. aureus 8325-4 were treated with SteLL (at 4 µg/mL and 16 µg/mL, corresponding 
to 2 × MIC and 8 × MIC, respectively), ciprofloxacin (0.78 µg/mL; 1 × MIC), or chloramphenicol (12.5 µg/mL; 
1 × MIC) for 3 h. Bacteria were centrifuged (9000 × g for 8 min at 4 °C) and fixed by resuspending in 100 µL Tris 
(10 mM; pH 7.5) and adding 1 mL of ethanol (77%). For staining, each sample (100 µL) was centrifuged as above 
and the cell pellet was then resuspended in 170 µL of a solution of ethidium bromide (20 µg/mL) and mithramycin 
(90 µg/mL). For each sample, a minimum of 15,000 cells were analyzed using an Apogee A10 instrument. Cell 
mass and DNA content were determined by the measurement of forward scattering (at LS1 detector) and fluores-
cence intensity (at FL2 channel), respectively40.
For fluorescence microscopy, S. aureus strain 8325-4 was grown exponentially at 37 °C in LB. 
SteLL (2 × MIC or 8 × MIC) or ciprofloxacin (1 × MIC) were added and samples were taken for DAPI 
(4′,6-diamidino-2-phenylindole) staining after 3 h. The images were recorded by fluorescence microscopic sys-
tem (Axio Imager Z2, Carl Zeiss, Germany).
SoS response assay. The induction of SOS response was measured using a derivative S. aureus 8325-4 
strain carrying a recA::lacZ fusion. Bacteria were grown exponentially in LB medium until an OD600 between 
0.1 and 0.2. Cells were treated with SteLL or ciprofloxacin (both at 0.5 × MIC) for 3 h70. Cells were permeabi-
lizated by toluene and β-galactosidase activity was measured using ONPG (ortho-Nitrophenyl-β-galactoside; 
Sigma-Aldrich).
Staphyloxanthin inhibition assay. Overnight cultures of S. aureus ATCC 29312 (a strong staphyloxan-
thin producer) were diluted (1:100) in LB medium and samples (1 mL) of this suspension were incubated with 
sub-inhibitory concentrations of SteLL (0.0625 × MIC, 0.125 × MIC, 0.25 × MIC, 0.5 × MIC). After overnight 
incubation at 37 °C, the tubes were centrifuged (9000 × g for 10 min), suspended with 1 mL of phosphate-buffered 
saline (PBS) and re-centrifuged. Bacteria cells were then photographed. Next, an assay to quantify carotenoid 
pigments (including staphyloxanthin) was performed. For this, each pellet was resuspended in methanol (0.2 mL) 
and incubated for 3 min at 55 °C. The methanol phase (supernatant) and cell debris were separated by centrifu-
gation (9000 × g for 10 min) and the pellets were submitted to entire pigment extraction procedure three more 
times. Finally, the absorbance of methanol extract was determined at 465 nm34.
Assays with mice peritoneal macrophages. Isolation of mice peritoneal macrophages. Peritoneal 
macrophages were obtained from inbred strains of C57BL/6 mice of both sexes at 8–10 weeks of age. Exudate 
cells were harvested by peritoneal lavage using 10 mL of ice-cold sterile phosphate-buffered saline (PBS) (pH 
7.2). After centrifugation at 120 × g for 5 min, the cell pellets were suspended in RPMI-1640 medium supple-
mented with bovine calf serum (10%; v/v), penicillin and streptomycin (100 U/mL) (all from Sigma-Aldrich). 
For all assays, macrophages (1 × 106 cells/mL) were cultured in 24- or 96-well plates, and non-adherent cells were 
removed. All animal experiments were performed according to the ethical standards of the CEUMA University 
and were approved by the ethics committee for animal experimentation of this institution (CEUA-CEUMA) 
(Protocol of Approval N° 107/14), which follows the principles of care with laboratory animals.
Determination of nitric oxide (NO) production and cell viability. For both assays, macrophages (1 × 106 cells/mL) 
were seeded in 96-well plates for 24 h at 37 °C and 5% CO2. The cells were then treated with SteLL (2, 4, 8 and 
16 µg/mL) for another 24 h. Next, the supernatant was used for determination of NO production, and the adher-
ent cells were assessed by the MTT assay (below). Untreated cells were used as negative control. LPS (Escherichia 
coli; 2000 ng/mL; Sigma-Aldrich) + INF-γ (100 ng/mL; BD Pharmingen) were used as inductors of macrophages 
activation (M1 macrophages), while IL-4 (400 ng/mL; BD Pharmingen) + IL-13 (400 ng/mL; BD Pharmingen) 
were used for induction of alternative activation (M2 macrophages). The assays were performed following the 
protocols described below in quadruplicate in two independent experiments. The results are expressed as the 
mean ± standard deviation (S.D.).
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•	 NO production: The measurement of NO production by peritoneal macrophages was determined using the 
Griess assay. Briefly, a 50 μL sample from the supernatant of each well was mixed with 50 μL of Griess reagent 
in a 96-wells plate. After incubation for 15 min at room temperature, the optical density was determined at 
540 nm with a microplate reader (Benchmark Plus, Bio-Rad, CA, US). The nitrite concentration (μmol/106 
cells) was quantified by extrapolation from a sodium nitrite standard curve for each experiment.
•	 MTT assay: Cell viability was evaluated using the MTT assay, which measures the metabolic conversion of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) salt to colored formazan dye. At the 
end of the incubation period, the medium was removed, and fresh RPMI medium containing 5 mg/mL MTT 
solution was added, and the sample was incubated for 3 h. Subsequently, the medium was removed, and the 
intracellular formazan product was dissolved in DMSO. The optical density (OD) was measured at 595 nm. 
Cell viability was expressed as the % of viable cells compared to the control.
Mitochondrial superoxide production. Mitochondrial superoxide anion production by the macrophages was 
evaluated using a MitoSOX™ Red Mitochondrial Superoxide Indicator (Molecular Probes). Peritoneal mac-
rophages were treated with SteLL (8 and 16 µg/mL) for 30 min. After trypsinization and washing with PBS, 
MitoSOX™ Reagent (1 mL, 5 μM) was added to the culture samples and incubated for 10 min at 37 °C, protected 
from light. The cells were washed three times with warm PBS and analyzed using a BD Accuri C6 Flow Cytometer 
(BD Biosciences, San Jose, CA, USA). The events (at least 10,000) were analyzed with FlowJo 7.6.1 software 
(TreeStar-Ashland, OR, USA).
Macrophage infection and treatment with SteLL. Overnight cultures of S. aureus 8325-4 were centrifuged at 
10,000 × g for 10 min, washed twice with PBS, and resuspended in PBS. In parallel, peritoneal macrophages 
(1 × 106 cells/mL) were seeded in a 96-wells plate for 24 h and infected with S. aureus 8325-4 at a ratio of 10:1 
(bacteria/cells) in the presence or absence of lectin (2, 4, 8 and 16 µg/mL). After 24 h, the supernatant was assayed 
for nitric oxide as described above.
Bacterial killing assay. The effects of SteLL on the bactericidal effect of peritoneal macrophages were evalu-
ated towards intracellular and extracellular bacteria. To quantify extracellular bacteria, aliquots of 4 µL of 
10-fold-diluted suspensions from cell supernatants were added to agar plates. For the measurement of intracel-
lular bacteria, the supernatants were removed and each well was washed 5× with ice-cold PBS containing trypan 
blue in order to remove extracellular bacteria. Following, the cells lysed after washing in 0.1 mL sterile water71. 
The cell lysates were 10-fold-diluted and added in agar plates. All plates were incubated at 37 °C for 24 h. After this 
period, the colonies were counted for the calculation of CFU/mL.
Measurement of cytokine release by macrophages. The levels of cytokines (TNFα, IL-6, IL-17A, IFN-γ, IL-4, 
IL-12 and IL-10) in the supernatant of macrophages were determined by using Mouse cytometric bead array 
(CBA) cytokine kits (BD Biosciences, Brazil) according with the manufacturer’s instructions. Analysis was per-
formed on a BD Accuri 6 flow cytometer. Results were calculated in CBA FCAP Array software (BD Biosciences, 
Brazil) and expressed as pg/mL.
In vivo infection model with Galleria mellonella. Survival assay. G. mellonella larvae (~200 mg) were 
randomly distributed in three experimental groups (n = 10). Two groups were infected by injection of 10 μL of 
a fresh S. aureus 8325-4 suspension (1 × 105 CFU/mL) into the last left proleg, followed by incubation at 37 °C. 
After 2 h, one group of animals received 10 μL of 4 μg/mL SteLL (2 × MIC) dissolved in PBS (resulting in a dose of 
0.2 mg/kg). The second group of animals was treated with PBS. The larvae were incubated at 37 °C, and the larval 
viability was determined daily for 4 days.
Quantification of S. aureus in G. mellonella hemolymph. G. mellonella larvae were infected with S. aureus and 
treated as described above. Each day, a total of 5 larvae were cut in the cephalocaudal direction with a scalpel 
blade and squeezed to remove the hemolymph. Each sample was 10-fold-diluted in PBS and 4 µL was plated on 
LB agar. After 24 h-incubation at 37 °C, the colonies were enumerated, and the results were expressed as CFU/mL.
Statistics analysis. All experiments were performed in quadruplicates and in at least two independent 
assays. Plotting of data was performed using GraphPad Prism 5. Experiments with p < 0.05 were considered 
significant and are stated in the results section. The survival plots for in vivo infection were performed using 
Kaplan-Meier analysis on pooled data for repetitive experiments. Statistical analysis was carried out with log-rank 
(Mantel-Cox) test for comparison of survival curves. Experiments with p < 0.05 were considered significant and 
are stated in the results section.
conclusion
Altogether, the findings of this study suggest that the SteLL impairs cell division of S. aureus without provok-
ing DNA damage. The lectin also alters bacteria metabolism resulting in a reduced staphyloxanthin production. 
These effects may be responsible for the anti-infective activity of SteLL in G. mellonella. Furthermore, we demon-
strate that SteLL increase the production of cytokines by uninfected macrophages and modulate the release of 
IL-17A and IFN-γ in S. aureus-infected macrophages. Taken together, these findings from both in vitro and in 
vivo studies suggest SteLL as a promising lead for the development of new anti-infective agents against S. aureus.
1 2Scientific RepoRtS |         (2019) 9:18159  | https://doi.org/10.1038/s41598-019-54616-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Data availability
The data used to build all graphs to support the findings of this study are available from the corresponding author 
upon request.
Received: 4 April 2019; Accepted: 18 November 2019;
Published: xx xx xxxx
References
 1. Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L. & Fowler, V. G. Jr. Staphylococcus aureus infections: epidemiology, 
pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28, 603–661, https://doi.org/10.1128/CMR.00134-14 
(2015).
 2. Lee, A. S. et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 4, 18033, https://doi.org/10.1038/nrdp.2018.33 
(2018).
 3. Bonar, E. A. et al. Joint Genomic and Proteomic Analysis Identifies Meta-Trait Characteristics of Virulent and Non-virulent 
Staphylococcus aureus Strains. Front Cell Infect Microbiol 8, 313, https://doi.org/10.3389/fcimb.2018.00313 (2018).
 4. Choudhary, K. S. et al. The Staphylococcus aureus Two-Component System AgrAC Displays Four Distinct Genomic Arrangements 
That Delineate Genomic Virulence Factor Signatures. Front Microbiol 9, 1082, https://doi.org/10.3389/fmicb.2018.01082 (2018).
 5. Choe, D. et al. Genome-scale analysis of Methicillin-resistant Staphylococcus aureus USA300 reveals a tradeoff between 
pathogenesis and drug resistance. Sci Rep 8, 2215, https://doi.org/10.1038/s41598-018-20661-1 (2018).
 6. de Jong, N. W. M. et al. Identification of a staphylococcal complement inhibitor with broad host specificity in equid Staphylococcus 
aureus strains. J Biol Chem 293, 4468–4477, https://doi.org/10.1074/jbc.RA117.000599 (2018).
 7. Gerlach, D. et al. Methicillin-resistant Staphylococcus aureus alters cell wall glycosylation to evade immunity. Nature 563, 705–709, 
https://doi.org/10.1038/s41586-018-0730-x (2018).
 8. Niemann, S. et al. Panton-Valentine Leukocidin associated with S. aureus osteomyelitis activates platelets via neutrophil secretion 
products. Sci Rep 8, 2185, https://doi.org/10.1038/s41598-018-20582-z (2018).
 9. Fraunholz, M. & Sinha, B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol 2, 43, https://doi.
org/10.3389/fcimb.2012.00043 (2012).
 10. Grosz, M. et al. Cytoplasmic replication of Staphylococcus aureus upon phagosomal escape triggered by phenol-soluble modulin 
alpha. Cell Microbiol 16, 451–465, https://doi.org/10.1111/cmi.12233 (2014).
 11. Horn, J., Stelzner, K., Rudel, T. & Fraunholz, M. Inside job: Staphylococcus aureus host-pathogen interactions. Int J Med Microbiol 
308, 607–624, https://doi.org/10.1016/j.ijmm.2017.11.009 (2018).
 12. Berends, E. T. M. et al. Staphylococcus aureus Impairs the Function of and Kills Human Dendritic Cells via the LukAB Toxin. MBio 
10, https://doi.org/10.1128/mBio.01918-18 (2019).
 13. Nakagawa, S. et al. Staphylococcus aureus Virulent PSMalpha Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-
Dependent Skin Inflammation. Cell Host Microbe 22, 667–677 e665, https://doi.org/10.1016/j.chom.2017.10.008 (2017).
 14. Li, J., Casanova, J. L. & Puel, A. Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation. 
Mucosal Immunol 11, 581–589, https://doi.org/10.1038/mi.2017.97 (2018).
 15. Hancock, R. E., Nijnik, A. & Philpott, D. J. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 10, 
243–254, https://doi.org/10.1038/nrmicro2745 (2012).
 16. Jandu, J. J. B. et al. Targeting the Immune System with Plant Lectins to Combat Microbial Infections. Front Pharmacol 8, 671, https://
doi.org/10.3389/fphar.2017.00671 (2017).
 17. Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat 
Rev Drug Discov 17, 35–56, https://doi.org/10.1038/nrd.2017.162 (2018).
 18. da Silva, L. C. et al. Immunomodulatory effects of pCramoll and rCramoll on peritoneal exudate cells (PECs) infected and non-
infected with Staphylococcus aureus. Int J Biol Macromol 72, 848–854, https://doi.org/10.1016/j.ijbiomac.2014.09.045 (2015).
 19. Batista, J. et al. Plant lectins ConBr and CFL modulate expression toll-like receptors, pro-inflammatory cytokines and reduce the 
bacterial burden in macrophages infected with Salmonella enterica serovar Typhimurium. Phytomedicine 25, 52–60, https://doi.
org/10.1016/j.phymed.2016.12.005 (2017).
 20. Dos Santos, B. S. et al. Application of Omics Technologies for Evaluation of Antibacterial Mechanisms of Action of Plant-Derived 
Products. Front Microbiol 7, 1466, https://doi.org/10.3389/fmicb.2016.01466 (2016).
 21. Farha, M. A. & Brown, E. D. Strategies for target identification of antimicrobial natural products. Nat Prod Rep 33, 668–680, https://
doi.org/10.1039/c5np00127g (2016).
 22. da Silva, L. C. & Correia, M. T. Plant lectins and Toll-like receptors: implications for therapy of microbial infections. Front Microbiol 
5, 20, https://doi.org/10.3389/fmicb.2014.00020 (2014).
 23. Ayaz Ahmed, K. B., Raman, T. & Veerappan, A. Jacalin capped platinum nanoparticles confer persistent immunity against multiple 
Aeromonas infection in zebrafish. Sci Rep 8, 2200, https://doi.org/10.1038/s41598-018-20627-3 (2018).
 24. Ferreira, G. R. S. et al. Antimicrobial potential of Alpinia purpurata lectin (ApuL): Growth inhibitory action, synergistic effects in 
combination with antibiotics, and antibiofilm activity. Microb Pathog 124, 152–162, https://doi.org/10.1016/j.micpath.2018.08.027 
(2018).
 25. Gomes, F. S., Procopio, T. F., Napoleao, T. H., Coelho, L. C. & Paiva, P. M. Antimicrobial lectin from Schinus terebinthifolius leaf. J 
Appl Microbiol 114, 672–679, https://doi.org/10.1111/jam.12086 (2013).
 26. da Silva, P. M. et al. Punica granatum sarcotesta lectin (PgTeL) impairs growth, structure, viability, aggregation, and biofilm 
formation ability of Staphylococcus aureus clinical isolates. International journal of biological macromolecules 123, 600–608 (2019).
 27. Liedke, S. C. et al. Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin 
oligomers. Sci Rep 7, 12187, https://doi.org/10.1038/s41598-017-12540-y (2017).
 28. Camaroti, J. R. S. L. et al. Sitophilus zeamais adults have survival and nutrition affected by Schinus terebinthifolius leaf extract and 
its lectin (SteLL). Industrial crops and products 116, 81–89 (2018).
 29. Ramos, D. B. M. et al. Evaluation of antitumor activity and toxicity of Schinus terebinthifolia leaf extract and lectin (SteLL) in 
sarcoma 180-bearing mice. J Ethnopharmacol 233, 148–157, https://doi.org/10.1016/j.jep.2019.01.011 (2019).
 30. Cruciani, M. et al. Staphylococcus aureus Esx Factors Control Human Dendritic Cell Functions Conditioning Th1/Th17 Response. 
Front Cell Infect Microbiol 7, 330, https://doi.org/10.3389/fcimb.2017.00330 (2017).
 31. Krishna, S. & Miller, L. S. Innate and adaptive immune responses against Staphylococcus aureus skin infections. Semin 
Immunopathol 34, 261–280, https://doi.org/10.1007/s00281-011-0292-6 (2012).
 32. Krakauer, T. Staphylococcal Superantigens: Pyrogenic Toxins Induce Toxic Shock. Toxins (Basel) 11, https://doi.org/10.3390/
toxins11030178 (2019).
 33. Jonsson, R., Struve, C., Jenssen, H. & Krogfelt, K. A. The wax moth Galleria mellonella as a novel model system to study 
Enteroaggregative Escherichia coli pathogenesis. Virulence 8, 1894–1899, https://doi.org/10.1080/21505594.2016.1256537 (2017).
 34. Silva, L. N. et al. Myricetin protects Galleria mellonella against Staphylococcus aureus infection and inhibits multiple virulence 
factors. Sci Rep 7, 2823, https://doi.org/10.1038/s41598-017-02712-1 (2017).
13Scientific RepoRtS |         (2019) 9:18159  | https://doi.org/10.1038/s41598-019-54616-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
 35. Ferro, T. A. et al. Cinnamaldehyde Inhibits Staphylococcus aureus Virulence Factors and Protects against Infection in a Galleria 
mellonella Model. Front Microbiol 7, 2052, https://doi.org/10.3389/fmicb.2016.02052 (2016).
 36. Carvalho, M., Melo, A., Aragão, C., Raffin, F. & Moura, T. Schinus terebinthifolius Raddi: chemical composition, biological 
properties and toxicity. Revista Brasileira de Plantas Medicinais 15, 158–169 (2013).
 37. Estevao, L. R. M. et al. Schinus terebinthifolius Raddi (Aroeira) leaves oil attenuates inflammatory responses in cutaneous wound 
healing in mice 1. Acta Cir Bras 32, 726–735, https://doi.org/10.1590/s0102-865020170090000005 (2017).
 38. da Silva, J. H. S. et al. Anti-Escherichia coli activity of extracts from Schinus terebinthifolius fruits and leaves. Nat Prod Res 32, 
1365–1368, https://doi.org/10.1080/14786419.2017.1344657 (2018).
 39. Salem, M. Z. M. et al. Antibacterial activity of extracted bioactive molecules of Schinus terebinthifolius ripened fruits against some 
pathogenic bacteria. Microb Pathog 120, 119–127, https://doi.org/10.1016/j.micpath.2018.04.040 (2018).
 40. Lobner-Olesen, A., Skarstad, K., Hansen, F. G., von Meyenburg, K. & Boye, E. The DnaA protein determines the initiation mass of 
Escherichia coli K-12. Cell 57, 881–889 (1989).
 41. Westfall, C. S. & Levin, P. A. Bacterial cell size: multifactorial and multifaceted. Annual review of microbiology 71, 499–517 (2017).
 42. Corrigan, R. M., Abbott, J. C., Burhenne, H., Kaever, V. & Gründling, A. c-di-AMP is a new second messenger in Staphylococcus 
aureus with a role in controlling cell size and envelope stress. PLoS pathogens 7, e1002217 (2011).
 43. Jorge, A. M., Hoiczyk, E., Gomes, J. P. & Pinho, M. G. EzrA contributes to the regulation of cell size in Staphylococcus aureus. PLoS 
One 6, e27542 (2011).
 44. Deforet, M., van Ditmarsch, D. & Xavier, J. B. Cell-Size Homeostasis and the Incremental Rule in a Bacterial Pathogen. Biophys J 109, 
521–528, https://doi.org/10.1016/j.bpj.2015.07.002 (2015).
 45. Campbell, J. et al. An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in 
Staphylococcus aureus. Antimicrob Agents Chemother 56, 1810–1820, https://doi.org/10.1128/AAC.05938-11 (2012).
 46. Coelho, L. et al. Lectins as antimicrobial agents. Journal of applied microbiology 125, 1238–1252 (2018).
 47. Simmons, L. A., Foti, J. J., Cohen, S. E. & Walker, G. C. The SOS Regulatory Network. EcoSal Plus 2008, https://doi.org/10.1128/
ecosalplus.5.4.3 (2008).
 48. Santos, V. F. et al. The Galactose-Binding Lectin Isolated from Vatairea macrocarpa Seeds Enhances the Effect of Antibiotics Against 
Staphylococcus aureus-Resistant Strain. Probiotics Antimicrob Proteins. https://doi.org/10.1007/s12602-019-9526-z (2019).
 49. Xiong, Y. Q., Yang, S. J., Tong, S. Y., Alvarez, D. N. & Mishra, N. N. The role of Staphylococcal carotenogenesis in resistance to host 
defense peptides and in vivo virulence in experimental endocarditis model. Pathog Dis 73, https://doi.org/10.1093/femspd/ftv056 (2015).
 50. Ni, S. et al. Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus. ACS Med 
Chem Lett 9, 233–237, https://doi.org/10.1021/acsmedchemlett.7b00501 (2018).
 51. Rubini, D. et al. Chitosan extracted from marine biowaste mitigates staphyloxanthin production and biofilms of Methicillin- 
resistant Staphylococcus aureus. Food Chem Toxicol 118, 733–744, https://doi.org/10.1016/j.fct.2018.06.017 (2018).
 52. Colasso, A. H. M. et al. The latex of Euphorbia tirucalli inhibits staphyloxanthin production and protects Tenebrio molitor larvae 
against Staphylococcus aureus infection. Nat Prod Res, 1–4, https://doi.org/10.1080/14786419.2019.1582036 (2019).
 53. Duarte, C. E. M. et al. A new TRAF-like protein from B. oleracea ssp. botrytis with lectin activity and its effect on macrophages. Int 
J Biol Macromol 94, 508–514, https://doi.org/10.1016/j.ijbiomac.2016.10.061 (2017).
 54. Bogdan, C. Nitric oxide and the immune response. Nat Immunol 2, 907–916, https://doi.org/10.1038/ni1001-907 (2001).
 55. Nathan, C. & Cunningham-Bussel, A. Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol 
13, 349–361, https://doi.org/10.1038/nri3423 (2013).
 56. Archer, N. K. et al. Interleukin-17A (IL-17A) and IL-17F Are Critical for Antimicrobial Peptide Production and Clearance of 
Staphylococcus aureus Nasal Colonization. Infect Immun 84, 3575–3583, https://doi.org/10.1128/IAI.00596-16 (2016).
 57. Greenlee-Wacker, M. C. & Nauseef, W. M. IFN-gamma targets macrophage-mediated immune responses toward Staphylococcus 
aureus. J Leukoc Biol 101, 751–758, https://doi.org/10.1189/jlb.4A1215-565RR (2017).
 58. Di Domenico, E. G. et al. Inflammatory cytokines and biofilm production sustain Staphylococcus aureus outgrowth and persistence: 
a pivotal interplay in the pathogenesis of Atopic Dermatitis. Sci Rep 8, 9573, https://doi.org/10.1038/s41598-018-27421-1 (2018).
 59. Jiang, X. et al. Micheliolide provides protection of mice against Staphylococcus aureus and MRSA infection by down-regulating 
inflammatory response. Sci Rep 7, 41964, https://doi.org/10.1038/srep41964 (2017).
 60. Dey, S. & Bishayi, B. Riboflavin along with antibiotics balances reactive oxygen species and inflammatory cytokines and controls 
Staphylococcus aureus infection by boosting murine macrophage function and regulates inflammation. J Inflamm (Lond) 13, 36, 
https://doi.org/10.1186/s12950-016-0145-0 (2016).
 61. de Melo, C. M. et al. Immunomodulatory response of Cramoll 1,4 lectin on experimental lymphocytes. Phytother Res 24, 1631–1636, 
https://doi.org/10.1002/ptr.3156 (2010).
 62. de Melo, C. M. et al. Cramoll 1,4 lectin increases ROS production, calcium levels, and cytokine expression in treated spleen cells of 
rats. Mol Cell Biochem 342, 163–169, https://doi.org/10.1007/s11010-010-0480-z (2010).
 63. de Oliveira, P. S. et al. Cratylia mollis 1, 4 lectin: a new biotechnological tool in IL-6, IL-17A, IL-22, and IL-23 induction and 
generation of immunological memory. Biomed Res Int 2013, 263968, https://doi.org/10.1155/2013/263968 (2013).
 64. Jandu, J. J. et al. Treatment with pCramoll Alone and in Combination with Fluconazole Provides Therapeutic Benefits in C. gattii 
Infected Mice. Front Cell Infect Microbiol 7, 211, https://doi.org/10.3389/fcimb.2017.00211 (2017).
 65. Gottschalk, S. et al. The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in 
Staphylococcus aureus. BMC Microbiol 13, 192, https://doi.org/10.1186/1471-2180-13-192 (2013).
 66. Olivier, A. C., Lemaire, S., Van Bambeke, F., Tulkens, P. M. & Oldfield, E. Role of rsbU and staphyloxanthin in phagocytosis and 
intracellular growth of Staphylococcus aureus in human macrophages and endothelial cells. The Journal of infectious diseases 200, 
1367–1370 (2009).
 67. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J Biol Chem 193, 
265–275 (1951).
 68. da Silva, A. P. et al. Antimicrobial Activity and Phytochemical Analysis of Organic Extracts from Cleome spinosa Jaqc. Front 
Microbiol 7, 963, https://doi.org/10.3389/fmicb.2016.00963 (2016).
 69. Zuo, G. Y. et al. Antimicrobial activity and synergy of antibiotics with two biphenyl compounds, protosappanins A and B from 
Sappan Lignum against methicillin-resistant Staphylococcus aureus strains. J Pharm Pharmacol 67, 1439–1447, https://doi.
org/10.1111/jphp.12433 (2015).
 70. Vestergaard, M., Paulander, W. & Ingmer, H. Activation of the SOS response increases the frequency of small colony variants. BMC 
Res Notes 8, 749, https://doi.org/10.1186/s13104-015-1735-2 (2015).
 71. Lin, Y. et al. Microbicidal Phagocytosis of Nucleus Pulposus Cells Against Staphylococcus aureus via the TLR2/MAPKs Signaling 
Pathway. Front Immunol 10, 1132, https://doi.org/10.3389/fimmu.2019.01132 (2019).
Acknowledgements
We would like thank Dr. Claudener Souza Teixeira from Universidade Federal do Maranhão (Chapadinha, 
Brazil) for sharing N-acetylglucosamine for the inhibition assay. We are also grateful for Prof. Dr. Hanne Ingmer 
from University of Copenhagen for kindly sharing the report strain. This work was funded by Fundação de 
Amparo à Pesquisa e Desenvolvimento Científico do Maranhão (UNIVERSAL-00998/16, COOPI-02860/16, 
1 4Scientific RepoRtS |         (2019) 9:18159  | https://doi.org/10.1038/s41598-019-54616-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
BEPP-02241/18, BM-02751/16, BIC-00682/19), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 
(Science without borders program; Process: 12179-13-2) and Conselho Nacional de Desenvolvimento Científico e 
Tecnológico (Process number: 426950/2018-6).
Author contributions
L.C.N.S., P.M.G.P., T.H.N., A.L.O. and K.A.K. conceived the study and performed the study design. T.H.N. and 
P.M.P.G. performed the purification of SteLL. I.M.S.F.L., C.M.B.F., H.S.M., D.M.S., B.S.C., and L.C.N.S. performed 
the microbiological assays. I.M.S.F.L., L.C.N.S., A.Z., D.M.S., L.S.S., B.S.C., S.L.V. and E.M.S. performed the assays 
with mouse macrophages. I.M.S.F.L., L.C.N.S., P.M.G.P., T.H.N., A.L.O. and K.A.K. wrote the paper. All author 
discussed the results and approved the final version of this manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-54616-x.
Correspondence and requests for materials should be addressed to L.C.N.d.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
